Eaton Vance Management’s Travere Therapeutics TVTX Stock Holding History

Eaton Vance Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$2.99M	Hold	121,514	–	–	﹤0.01%	923
2022 Q2	$2.94M	Hold	121,514	–	–	﹤0.01%	957
2022 Q1	$3.13M	Hold	121,514	–	–	﹤0.01%	1034
2021 Q4	$3.77M	Sell	121,514 -56,207	-32%	-$1.58M	﹤0.01%	855
2021 Q3	$4.31M	Hold	177,721	–	–	0.01%	756
2021 Q2	$2.59M	Buy	177,721 +135,606	+322%	+$2.67M	﹤0.01%	952
2021 Q1	$1.05M	Buy	+42,115	New	+$1.16M	﹤0.01%	1120

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Eaton Vance Management's TVTX Position: Q3 2022 in Review

Eaton Vance Management held its Travere Therapeutics (TVTX) position steady in Q3 2022 at 121,514 shares worth $2.99M. The position accounts for ﹤0.01% of the portfolio, ranked #923.

Eaton Vance Management first reported a position in TVTX in Q1 2021 and has held it in 7 quarters since. The position peaked at $4.31M in Q3 2021. 171 funds tracked by Wall St. Rank hold TVTX as of Q3 2022.

Eaton Vance Management held 121,514 shares of Travere Therapeutics worth $2.99M as of Q3 2022.
Eaton Vance Management left its Travere Therapeutics share count unchanged in Q3 2022.
Travere Therapeutics made up ﹤0.01% of Eaton Vance Management's portfolio in Q3 2022, its #923 holding.
Eaton Vance Management first reported a position in Travere Therapeutics in Q1 2021 and has held it in 7 quarters since.
Eaton Vance Management's Travere Therapeutics position peaked at $4.31M in Q3 2021.
171 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.